After four & # 39; & # 39 years; work, today published scientific study team & # 39; academic researchers led by the University & # 39; Concepción, María Inés Barría, and gives an account of the effectiveness of the treatment against the hanta virus developed.
Work published by the international magazine Translational Medicine Science, Indicating that the antibodies in human patients survived the disease could protect the animals that were part of the study.
It is a therapeutic vaccine based on monoclonal antibodies derived from the & # 39; persons who acquired but managed to survive the disease. Out of 27 blood samples from these patients, the team selected two molecules MIB22 and JL16, Those who were administered to a group & # 39; rodents previously infected three days before b & # 39; & # 39 lethal dose; the hanta virus.
The result? Not only reached prevent disease in all animals but also, analyze them, did not have the virus in their body. It was also found that both molecules can be used together. The researchers suggest that antibodies able to recognize and neutralize the virus
The good news, besides the results of & # 39; successful, is that the antibodies used are human antibodies to be put quickly into a study in & # 39; people is the following step in & # 39; this -investigazzjoni.
Last year, 90 people were infected with Hantavirus Andes, of which 24 have died from Hantavirus Cardiopulmonary Syndrome. To date, m & # 39; there is no effective treatment for this disease.